Hong Kong Pharmaceuticals Stock News

Li Ning earnings put fresh focus on the stock Li Ning (SEHK:2331) has moved back into focus after reporting first half 2026 results, with both sales and net income higher than a year earlier. Investors now have fresh numbers to assess the stock. See our latest analysis for Li Ning. The earnings update has arrived after a period of pressure on Li Ning shares, with the stock closing at HK$14.46 and recording a 90 day share price return that fell 20.98% and a 5 year total shareholder return that...

Even though Kidsland International Holdings Limited ( HKG:2122 ) has fallen by 37% over the past week , insiders who...

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

It's been a pretty great week for Everest Medicines Limited ( HKG:1952 ) shareholders, with its shares surging 18% to...

Celebrations may be in order for Value Partners Group Limited ( HKG:806 ) shareholders, with the analysts delivering a...

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...

Ocean One Holding Ltd. ( HKG:9876 ) stock is about to trade ex-dividend in 4 days. The ex-dividend date is two business...

It looks like HK Electric Investments and HK Electric Investments Limited ( HKG:2638 ) is about to go ex-dividend in...

Safety Godown Company, Limited ( HKG:237 ) stock is about to trade ex-dividend in four days. The ex-dividend date...

Sun Hung Kai stock has barely moved over the past month, even though traders just watched another set of resilient earnings land with a thud. The headline was an attributable profit of HK$688 million for H1 2026 and a higher interim dividend of HK$0.13 per share, all delivered while net gearing edged down to 27.1%. The market reaction looks muted for a business that continues to convert its credit and alternatives franchise into cash returns, which puts sentiment rather than fundamentals in...

Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Asia Allied...

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...

Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Hong Kong...

It looks like China Gas Holdings Limited ( HKG:384 ) is about to go ex-dividend in the next four days. The ex-dividend...

Giant Biogene Holding Co., Ltd. ( HKG:2367 ) last week reported its latest interim results, which makes it a good time...

As Asian markets navigate a landscape marked by fluctuating economic indicators and geopolitical tensions, investors are increasingly exploring diverse opportunities to enhance their portfolios. Penny stocks, despite their antiquated name, continue to intrigue investors with the potential for substantial growth when rooted in strong financials. This article examines three notable penny stocks in Asia that showcase robust balance sheets and the capacity for long-term value creation.

China East Education Holdings heads into the post earnings session with the stock down about 4% over the past week and roughly 21% over three months, even as the latest half year numbers tell a firmer story. H1 2026 revenue reached ¥2,417.9m and basic earnings per share came in at ¥0.2052, feeding into trailing twelve month net income of ¥808.3m. The near term trading pressure sits against a longer term picture of solid earnings growth, higher net profit margins and a P/E of 9.3x. That...

Keymed Biosciences stock has cooled in recent weeks, with the share price down about 10.6% over the past month even after moving into the black over the last year. Today's earnings story is all about profit, not hype. Basic earnings per share for the first half of 2026 came in at ¥4.29, flipping from losses in 2025, and trailing twelve month earnings now support a P/E of 25.4x. The market is treating that P/E as a question mark. The key issue now is whether investors see this new...

China Starch Holdings walked into these H1 results with a weak share price trend and a rich valuation, trading on a 41.7x P/E against lower industry multiples. The market had already marked the stock down over the past month, yet today’s earnings story revolves less around revenue and more around profit quality. Net income from ongoing operations for the trailing year is only slightly positive and heavily flattered by a one off gain of C¥9.7m, while the trailing net margin sits at just 0.2%...

Earnings trigger shifts focus to profit pressure and computing power growth China Unicom (Hong Kong) (SEHK:762) just released its 2026 interim results, giving you fresh numbers on revenue, profit pressure and the fast growing computing power business that management continues to highlight. See our latest analysis for China Unicom (Hong Kong). The earnings announcement on 18 August has arrived after a weak stretch for China Unicom (Hong Kong), with the share price down 29.34% year to date and...

Yuexiu Transport Infrastructure stock closed at HK$3.66 after the market had a day to digest its H1 2026 report, leaving a company with a discounted P/E and a big valuation gap that is trading as if very little has changed. The headline is profitability pressure. Trailing net profit margin is 10%, which is lower than last year’s 12.8%, even as trailing twelve month earnings from continuing operations sit at ¥893.6m. For an infrastructure toll and transport operator, that squeeze on earnings...

China Resources Beer closed at HK$20.54, capping a three month slide of nearly 19%, yet the fresh half year numbers tell a more nuanced story than the share chart suggests. In H1 2026, revenue came in at ¥24,240m with basic earnings per share of ¥1.59. Trailing net margin has compressed to 7.2% from 15% a year earlier. The real tension for long term holders now sits in that squeeze between weaker reported profitability and a valuation on 20.8x P/E that still sits above sector averages. Is...

Sisram Medical stock has been under pressure, down about 27% over the past three months, yet today’s H1 2026 earnings story is not just about the share price slide. The headline is a clear profit squeeze. Revenue edged up to US$171.4m, but adjusted net profit was only US$5.04m, and the net result swung to a small loss. For a medical aesthetics equipment and injectables business that trades on a P/E of 11.1x and pays a 4.46% dividend, the real question now is how much short term margin pain...

Sun Hung Kai (SEHK:86) drew fresh investor attention on 19 August 2026 after reporting interim results that included HK$688 million in attributable profit, a higher interim dividend of HK$0.13 per share, and ongoing share repurchases. See our latest analysis for Sun Hung Kai. The latest interim results and dividend increase appear to have supported sentiment, with Sun Hung Kai’s share price showing a 3% 1 day return and a 4.3% 7 day return. The 3 year total shareholder return of 89.94% and 5...